Can the pharmaceutical industry reduce attrition rates?
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Part of the attrition may be due to low animal-to-human translational success rates; the so-called “translational failure” [3].”
From Animal to human translation: a systematic scoping review of reported concordance rates (2019) · cites this paper as [3]
In the citing paper
“Even so, late-stage attritions are still frequent [11].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [11]
In the citing paper
“Inhibition of the hERG channel can be an indicator of the APD prolongation and cardiotoxicity in early stages of drug development [11].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [11]
In the citing paper
“Less than 20 years ago, developing a drug took ~12 years, cost under a billion dollars, and the biggest challenges were failures due to efficacy or toxicity-induced attrition2.”
From Exploiting machine learning for end-to-end drug discovery and development (2019) · cites this paper as [2]
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265 · cited 1×
“In 2001, the costs of discovering and developing a drug were of the order of US d804 millio”
BackgroundRoberds, S. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1317 · Cited by 705 · cited 1×
“We have, in a similar manner, provided very strong evidence that inhibition of β-secretase inhibits the production of amyloid-β in knockout mic”
ResultGowen, M., Lazner, F., Dodds, R., Kapadia, R., Feild, J., Tavaria, M., Bertoncello, I., Drake, F., Zavarselk, S., Tellis, I., et al. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.10.1654 · Cited by 490
Self-citationMa, P., & Zemmel, R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd884 · Cited by 174
Booth, B. L., Glassman, R. H., & Ma, P. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1158 · Cited by 84
An animal model for pycnodysostosis: the role of cathepsin K in bone remodelling
Lazner, F., Gowen, M., & Kola, I. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01563-4 · Cited by 18 · cited 1×
“and that cathepsin K is involved in bone resorption (further compelling proof of mechanism is provided by humans with pycnodysostosi”
BackgroundSelf-citation2003 approvals: a year of innovation and upward trends
Frantz, S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1327 · Cited by 15
Research works printed but not linked: 4
- Kola, I. & Rafferty, M. New technologies that may impact drug discovery in the 5–10 year timeframe workshop. 2002 Biomed. Expo Ann Arbor Michigan (data derived from Prous Science, Drugs News Prospect (2002).
- Fearn, C. J. IMS Health. The World Pharmaceutical Market Presented at the Strategic Management Review, Australia, 19–20 June (2002).
- Benjamin, G. A. & Lumley, C. E. Industry Success Rates 2003 Including Trends in Success Rates CMR Report Number 03–202 R (CMR International Surrey, UK, 2003).
- Van den Haak, M. A., Palachandran, J. & Benjamin, G. A. Performance Metrics in Global Pharmaceutical R&D, Company specific review 2002 for Merck & Co. (CMR International, Surrey, UK, 2003).
Cited by
Items 801–900 of 1,025
Advances in multiparameter optimization methods for de novo drug design
Segall, M. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.913565 · Cited by 71
“Interestingly, the causes for failure have changed over time; in 1991, 39% of failures in development were attributed to poor PK [4], but by 2000 this had fallen to an estimated 10% [1].”
BackgroundThe case for induced pluripotent stem cell‐derived cardiomyocytes in pharmacological screening
Khan, J. M., Lyon, A. R., & Harding, S. E. (2013) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02118.x · Cited by 63
“Drug discovery and toxicology: the need for a new experimental system There is a vast attrition in the number of drugs developed for potential therapeutic use during the transition from the laboratory bench to hospital bedside, with 89% of drugs that pass current in vitro and animal model screening tests being withdra…”
BackgroundThe emerging role of in vitro electrophysiological methods in CNS safety pharmacology
Accardi, M. V., Pugsley, M. K., Forster, R. P., Troncy, É., Huang, H., & Authier, S. (2016) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2016.03.008 · Cited by 71
Refinement, Reduction, and Replacement of Animal Toxicity Tests by Computational Methods
Ford, K. A. (2016) · ILAR Journal · doi:10.1093/ilar/ilw031 · Cited by 72
“Toxicity accounts for up to 50% of failures in preclinical drug development (Cook et al. 2014; Kola and Landis 2004), indicating that there is a great need for rapid and reliable computational programs to assist in the prediction of toxicological events.”
BackgroundOgura, K., Sato, T., Yuki, H., & Honma, T. (2019) · Scientific Reports · doi:10.1038/s41598-019-47536-3 · Cited by 71
Polson, A. G., & Fuji, R. N. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01916.x · Cited by 66
“…of preclinical studies may never be fully achievable and the success rate for new drug approvals remains low due to failures of efficacy and safety (Kola and Landis, 2004; Reichert and Wenger, 2008), it is valuable to ask where have our preclinical models been successfully predictive and where…”
BackgroundQuantified proarrhythmic potential of selected human embryonic stem cell-derived cardiomyocytes
Jonsson, M. K. B., Duker, G., Tropp, C., Andersson, B., Sartipy, P., Vos, M. A., & van Veen, T. A. B. (2010) · Stem Cell Research · doi:10.1016/j.scr.2010.02.001 · Cited by 65
Key indicators of phase transition for clinical trials through machine learning
Feijoo, F., Palopoli, M., Bernstein, J., Siddiqui, S., & Albright, T. E. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.12.014 · Cited by 58
Identifying the immunomodulatory components of helminths
Shepherd, C., Navarro, S., Wangchuk, P., Wilson, D., Daly, N. L., & Loukas, A. (2015) · Parasite Immunology · doi:10.1111/pim.12192 · Cited by 61
Clinical trials in the era of personalized oncology
Maitland, M. L., & Schilsky, R. L. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20135 · Cited by 74
“Strikingly, compared with the rest of medicine, oncology has been one of the worst underperformers in bringing new agents through the critical path.(4,5) In the introduction, we explained that the transition into the era of personalized oncology raises 2 concurrent and competing challenges: 1) to conduct clinical tria…”
BackgroundCummings, J., Hodgkinson, C., Odedra, R., Sini, P., Heaton, S. P., Mundt, K. E., Ward, T. H., Wilkinson, R. W., Growcott, J., Hughes, A., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2136 · Cited by 64
“Nowhere is this more pertinent than in the complex arena of anticancer drug development, where traditionally the rate of compound attrition is high and success in the clinic is low (2, 3).”
BackgroundGundala, S. R., & Aneja, R. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0355 · Cited by 79
“due to debilitating toxicity, limited efficacy, or emergence of drug resistance (3).”
BackgroundLow-Turnover Drug Molecules: A Current Challenge for Drug Metabolism Scientists
Hutzler, J. M., Ring, B. J., & Anderson, S. R. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.066431 · Cited by 67
“ment in later-stage drug candidate attrition (Kola and Landis, 2004).”
A TRACER 3D Co-Culture tumour model for head and neck cancer
Young, M. C., Rodenhizer, D., Dean, T., D’Arcangelo, E., Xu, B., Ailles, L., & McGuigan, A. P. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.01.038 · Cited by 70
What can nanosafety learn from drug development? The feasibility of “safety by design”
Hjorth, R., van Hove, L., & Wickson, F. (2017) · Nanotoxicology · doi:10.1080/17435390.2017.1299891 · Cited by 72
“Approximately one third of this clinical attrition is due to safety concerns (Kola & Landis, 2004) and improving the predictability of failure before entering clinical trials by 10% is estimated to save a company approximately $100 million (Sasseville et al., 2004).”
BackgroundChallenges for nationwide vaccine delivery in African countries
Songane, M. (2017) · International Journal of Health Economics and Management · doi:10.1007/s10754-017-9229-5 · Cited by 75
Efficacy of Tilorone Dihydrochloride against Ebola Virus Infection
Ekins, S., Lingerfelt, M. A., Comer, J. E., Freiberg, A. N., Mirsalis, J. C., O'Loughlin, K., Harutyunyan, A., McFarlane, C., Green, C. E., & Madrid, P. B. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01711-17 · Cited by 65
“A significant percentage of drug candidate attrition can be attributed to problems that arise from pharmacokinetic (PK) processes (38, 39).”
BackgroundPharmacokinetics of lipid-drug conjugates loaded into liposomes
Signorell, R. D., Luciani, P., Brambilla, D., & Leroux, J. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.04.003 · Cited by 71
“Poor biopharmaceutical/ pharmacokinetic (PK) properties are one of the reasons for this unfortunate outcome [2, 3].”
BackgroundParthiban, A., & Makam, P. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104379 · Cited by 65
Jacobson, P., & Parmet, W. E. (2007) · JAMA · doi:10.1001/jama.297.2.205 · Cited by 65
“Only 5% of all cancer drugs that enter clinical testing are approved for patient use; among cancer drugs assessed in phase 2 trials, only 30% proceed to phase 3 assessment.(17) During clinical trials for all drugs from 1981-1992, attrition (ie, abandonment) occurred for 3 reasons: safety concerns (including toxicity)…”
BackgroundModeling of Patient-Derived Xenografts in Colorectal Cancer
(2017) · doi:10.1158/1535-7163.mct-16-0721 · Cited by 64
“These failures highlighting the need for novel strategies of predicting clinical efficacy before drugs enter the clinic (37).”
BackgroundDelays in New Drug Applications in Japan and Industrial R&D Strategies
Hirai, Y., Kinoshita, H., Kusama, M., Yasuda, K., Sugiyama, Y., & Ono, S. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.215 · Cited by 64
Bednarczyk, D. (2010) · Analytical Biochemistry · doi:10.1016/j.ab.2010.06.012 · Cited by 64
“pharmacokinetic/bioavailability reasons [2].”
Integration of in silico and in vitro platforms for pharmacokinetic–pharmacodynamic modeling
Sung, J. H., Esch, M. B., & Shuler, M. L. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.496251 · Cited by 64
“In fact, unforeseen toxicity and the lack of efficacy have been cited as the primary reasons behind the high attrition rate in the drug development process, accounting for ~ 60% of failures [3].”
BackgroundWindow-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology
Glimelius, B. L. G., & Lahn, M. M. F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq622 · Cited by 65
Signal Detection and Placebo Response in Schizophrenia: Parallels with Depression
Mallinckrodt, C. H., Zhang, L., Prucka, W. R., & Millen, B. A. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4282 · Cited by 64
Carvalho, S., Levi‐Schaffer, F., Sela, M., & Yarden, Y. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13450 · Cited by 72
“These reasons underlie, in part, the relatively low attrition rate of engineered antibodies, as compared with other drug families, in clinical trials (Kola and Landis, 2004).”
BackgroundHultman, I., Vedin, C., Abrahamsson, A., Winiwarter, S., & Darnell, M. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00396 · Cited by 63
Screening a Natural Product-Based Library against Kinetoplastid Parasites
Zulfiqar, B., Jones, A., Sykes, M. L., Shelper, T., Davis, R. A., & Avery, V. M. (2017) · Molecules · doi:10.3390/molecules22101715 · Cited by 64
“Despite the new drug leads currently in clinical trials for leishmaniasis [21–23], HAT [24–26] and Chagas disease [27], there exists a high attrition rate [28,29] and new molecules with novel mechanisms of action are required.”
BackgroundNanobodies: New avenues for imaging, stabilizing and modulating GPCRs
Groof, T. W. M. D., Bobkov, V., Heukers, R., & Smit, M. J. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.01.021 · Cited by 68
“However, obtaining small molecules with high affinity, potency and selectivity is still a major challenge in the drug discovery process (Sriram and Insel, 2018; Kola and Landis, 2004).”
Ge, P., Niu, B., Wu, Y., Xu, W., Li, M., Sun, H., Zhou, H., Zhang, X.-K., & Xie, J. (2019) · Chemical Engineering Journal · doi:10.1016/j.cej.2019.123228 · Cited by 64
Recent advances in human respiratory epithelium models for drug discovery
Yaqub, N., Wayne, G. J., Birchall, M., & Song, W. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107832 · Cited by 68
Getting a Handle on Neuropharmacology by Targeting Receptor-Associated Proteins
Maher, M. P., Matta, J. A., Gu, S., Seierstad, M., & Bredt, D. S. (2017) · Neuron · doi:10.1016/j.neuron.2017.10.001 · Cited by 64
Yukawa, T., & Naven, R. T. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00536 · Cited by 68
Nobiletin as a chemopreventive natural product against cancer, a comprehensive review
Chen, Y., Liang, J.-J., Wang, D.-L., Chen, J., Cao, J., Wang, Y., & Sun, C. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2030297 · Cited by 66
Huang, L., Wu, X., & Chen, J. Y. (2012) · PROTEOMICS · doi:10.1002/pmic.201200337 · Cited by 71
“According to a decade research on drug failures [3], among all the causes of failures, concerns over drug safety (toxicology and clinical safety) have risen significantly (rising up approximately from 21% to 32% during the decade 1999– 2000), while concerns over drug efficacy have dropped a little…”
BackgroundBaranczewski, P., Stańczak, A., Kautiainen, A., Sandin, P., & Edlund, P. (2006) · PubMed · Cited by 63
Biomarkers in Pharmaceutical Research
Zhao, X., Modur, V., Carayannopoulos, L. N., & Laterza, O. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.231712 · Cited by 77
Validation of Early Human Dose Prediction: A Key Metric for Compound Progression in Drug Discovery
Page, K. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00840 · Cited by 64
Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology
Garralda, E., Dienstmann, R., & Tabernero, J. M. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_180460 · Cited by 67
Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact
de Vrueh, R. L. A., & Crommelin, D. J. A. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2192-5 · Cited by 63
“Despite the promise, these major advances in science have not yet increased the success rate of moving a compound from lab bench to first-in- man to approval and into medical practice (6,7).”
BackgroundTissue-engineered human 3D model of bladder cancer for invasion study and drug discovery
Goulet, C. R., Bernard, G., Chabaud, S., Couture, A., Langlois, A., Neveu, B., Pouliot, F., & Bolduc, S. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.08.041 · Cited by 66
Biofabrication of neural microphysiological systems using magnetic spheroid bioprinting
Bowser, D. A., & Moore, M. J. (2019) · Biofabrication · doi:10.1088/1758-5090/ab41b4 · Cited by 66
Allosteric Modulation of Metabotropic Glutamate Receptors
Sheffler, D. J., Gregory, K. J., Rook, J. M., & Conn, P. J. (2011) · Advances in pharmacology · doi:10.1016/b978-0-12-385952-5.00010-5 · Cited by 72
Weka Machine Learning for Predicting the Phospholipidosis Inducing Potential
Ivanciuc, O. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608786786589 · Cited by 71
Pharmacogenomics, Evidence, and the Role of Payers
Deverka, P. A. (2009) · Public Health Genomics · doi:10.1159/000189627 · Cited by 66
Developing predictive molecular maps of human disease through community-based modeling
Derry, J. M. J., Mangravite, L. M., Suver, C., Furia, M. D., Henderson, D., Schildwachter, X., Bot, B., Izant, J., Sieberts, S. K., Kellen, M. R., et al. (2012) · Nature Genetics · doi:10.1038/ng.1089 · Cited by 61
“This is largely due to the very high attrition rate for compounds in clinical development due to lack of efficacy in phase II trials: the success rate for progression of compounds from first-in-man studies to approved drug is only 11% 2 .”
BackgroundNoor, F., Niklas, J., Müller‐Vieira, U., & Heinzle, E. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.03.011 · Cited by 67
New approaches for improving outcomes in breast cancer in Europe
Leo, A. D., Curigliano, G., Dieras, V. C., Malorni, L., Sotiriou, C. P., Swanton, C., Thompson, A. M., Tutt, A. N. J., & Piccart, M. J. (2015) · The Breast · doi:10.1016/j.breast.2015.03.001 · Cited by 67
“The development of new drugs for breast cancer is hindered by high cost, low likelihood of success due to high attrition rates and poor understanding of the subpopulations that benefit from their use [39].”
BackgroundUchida, Y., Wakayama, K., Ohtsuki, S., Chiba, M., Ohe, T., Ishii, Y., & Terasaki, T. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.214536 · Cited by 66
“The proportion was just 8% for central nervous system (CNS)–acting drugs during the period 1991–2000 (Kola and Landis, 2004), and also no greater during the period 2000–2008 (Yagi and Ohkubo, 2010).”
BackgroundThakkar, S., chen, M., Fang, H., Liu, Z., Roberts, R., & Tong, W. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1383154 · Cited by 61
Oncologic Phase 0 Trials Incorporating Clinical Pharmacodynamics: from Concept to Patient
Doroshow, J. H., & Parchment, R. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4562 · Cited by 62
“The leading cause of attrition in clinical trials of novel oncologic therapeutics is now a lack of clinical activity (rather than toxicity), and unfortunately, only 5% to 10% of the molecules that are subjects of Investigational New Drug (IND) applications progress beyond early phases of development (1).”
BackgroundPrimary hepatocytes as a model to analyze species-specific toxicity and drug metabolism
Tuschl, G., Lauer, B., & Mueller, S. O. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.7.855 · Cited by 62
“Today, most drug candidates are stopped in clinical phases, most frequently owing to low efficacy or unpredicted toxicity in humans [3] .”
BackgroundNiazi, S. K. (2025) · Pharmaceuticals · doi:10.3390/ph18091271 · Cited by 61
“Each stage is characterized by high attrition rates, with only 1 in 5000 discovered compounds ultimately reaching market approval [17].”
Defining and characterizing drug/compound function
Kenakin, T., & Williams, M. J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.07.033 · Cited by 69
Structural Bioinformatics of the Interactome
Petrey, D., & Honig, B. (2014) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-051013-022726 · Cited by 59
“This “network pharmacology” approach is expected to address several important problems in drug design, where ever increasing numbers of drug candidates fail to pass clinical trials (102).”
BackgroundEconomic Opportunities and Challenges for Pharmacogenomics
Deverka, P. A., Vernon, J. A., & McLeod, H. L. (2010) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105805 · Cited by 73
Buckmaster, P. S., Wen, X., Toyoda, I., Gulland, F. M. D., & Bonn, W. G. V. (2013) · The Journal of Comparative Neurology · doi:10.1002/cne.23509 · Cited by 62
“…available to investigate mechanisms of temporal lobe epilepsy and develop new treatments (Buckmaster, 2004), but differences in the brains of rodents versus humans may contribute to the poor success rate of translating treatments for neurological disorders to human patients (Kola and Landis, 2004).”
BackgroundHassan, S. S., Tiwari, S., Guimarães, L. C., Jamal, S. B., Folador, E. L., Barve, N., Soares, S. D. C., de Almeida, S. S., Ali, A., Islam, A., et al. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-s7-s3 · Cited by 67
“Such practices are laborious, time consuming and require high investments [24, 25].”
BackgroundHuang, X., Ning, J., Li, Y., Estey, E. H., Issa, J. J., & Berry, D. A. (2009) · Statistics in Medicine · doi:10.1002/sim.3578 · Cited by 66
“We classify short-term response into four categories based on patient status at the end of treatment period: (1) resistance to treatment or death, (2) stable disease, (3) partial remission (PR), and (4) CR.”
MethodThe right compound in the right assay at the right time: an integrated discovery DMPK strategy
Ballard, P. G., Brassil, P. J., Bui, K., Dolgos, H., Petersson, C., Tunek, A., & Webborn, P. J. H. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2012.691099 · Cited by 65
“Foremost of these over the last 15 years has been early screening and optimization of drug metabolism and pharmacokinetics (DMPK) where attrition resulting from these factors has been reduced from 40% in 1990 to 10% in 2000 (Kola and Landis, 2004).”
BackgroundAlelyunas, Y. W., Empfield, J. R., McCarthy, D. J., Spreen, R. C., Bui, K., Pelosi-Kilby, L., & Shen, C. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.10.068 · Cited by 64
“Kola and Landis (2004) pointed out that safety and the lack of efficacy have emerged as the major causes for drug attrition in 2000 compared to 1990.1 In 2007, we were aware of two drugs that failed FDA approval: Bifeprunox for antipsychotic and Rimonabant for antiobesity indications.”
BackgroundInfluentialLeung, D., Lamberto, D. J., Liu, L., Kwong, E. C., Nelson, T. D., Rhodes, T. A., & Bak, A. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.05.003 · Cited by 61
Alelyunas, Y. W., Liu, R., Pelosi-Kilby, L., & Shen, C. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.02.007 · Cited by 61
Application of NMR and Molecular Docking in Structure-Based Drug Discovery
Stark, J. L., & Powers, R. (2011) · Topics in current chemistry · doi:10.1007/128_2011_213 · Cited by 70
“Approximately 80–90% of drugs that reach the clinical testing phase fail to make it to market [3, 4].”
Aging Biology and Novel Targets for Drug Discovery
Le Couteur, D. G., McLachlan, A. J., Quinn, R. J., Simpson, S. J., & de Cabo, R. (2012) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glr095 · Cited by 60
“Such an outcome is unfortunately typical in drug development where toxicology and clinical safety are the major reason for attrition of NCEs during the drug development process (60).”
BackgroundModeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer
Junttila, M. R., Devasthali, V., Cheng, J. H., Castillo, J., Metcalfe, C., Clermont, A. C., Otter, D. D., Chan, E., Bou-Reslan, H., Cao, T., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0030 · Cited by 62
“In KRAS-mutant PDAC, there are reports of genetic evidence supporting that the PI3K pathway supersedes RAS– RAF–MEK signaling (11), as well as reports to the contrary (12).”
BackgroundZhang, X., Wang, T., Wang, P., & Hu, N. (2016) · Micromachines · doi:10.3390/mi7070122 · Cited by 58
“Drug-induced cardiotoxicity accounts for a large fraction of safety-related drug attrition [2,3].”
BackgroundCyrenne, B. M., Lewis, J. M., Weed, J. G., Carlson, K. R., Mirza, F. N., Foss, F. M., & Girardi, M. (2017) · Blood · doi:10.1182/blood-2017-06-792150 · Cited by 64
Nanobodies detecting and modulating GPCRs outside in and inside out
Heukers, R., Groof, T. W. M. D., & Smit, M. J. (2019) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2019.01.003 · Cited by 66
Kap, Y. S., Laman, J. D., & Hart, B. A. ‘. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9178-y · Cited by 61
“The current success rate of new drugs varies from 20% for cardiovascular disorders to only about 8% for diseases of the CNS and reflects the predictive quality of the available preclinical animal models (Kola and Landis 2004).”
BackgroundKikkawa, R., Yamamoto, T., Fukushima, T., Yamada, H., & Horii, I. (2005) · The Journal of Toxicological Sciences · doi:10.2131/jts.30.61 · Cited by 65
Atienzar, F. A., Blomme, E. A., Chen, M., Hewitt, P., Kenna, J. G., Labbe, G., Moulin, F., Pognan, F., Roth, A. B., Suter-Dick, L., et al. (2016) · BioMed Research International · doi:10.1155/2016/9737920 · Cited by 59
Current Modeling Methods Used in QSAR/QSPR
Yee, L. C., & Wei, Y. C. (2012) · Wiley eBooks · doi:10.1002/9783527645121.ch1 · Cited by 75
Clinical Translation of Stem Cell Therapies: A Bridgeable Gap
Cuende, N., & Izeta, A. (2010) · Cell stem cell · doi:10.1016/j.stem.2010.05.005 · Cited by 60
Impact of microdosing clinical study — Why necessary and how useful?
Sugiyama, Y., & Yamashita, S. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.09.010 · Cited by 67
“Now, success probability of new drug candidates in the clinical trial is reported to be less than 10% [5].”
BackgroundTowards a sustainable system of drug development
Moors, E. H. M., Cohen, A. F., & Schellekens, H. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.03.004 · Cited by 60
“This means that the scientific productivity of the pharma industry has been poor for the past decade, because attrition rates in clinical trials have also climbed steeply [2,3], regulations are becoming more difficult [4] and market conditions are getting harsher [5,6].”
Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules
Luker, T. J., Alcaraz, L., Chohan, K. K., Blomberg, N., Brown, D. S., Butlin, R. J., Elebring, T., Griffin, A. M., Guile, S. D., St-Gallay, S. A., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.07.074 · Cited by 60
Chen, H.-R., Sherr, D. H., Hu, Z., & DeLisi, C. (2016) · BMC Medical Genomics · doi:10.1186/s12920-016-0212-7 · Cited by 64
“The high cost and the long time required to bring drugs into commerce [1 – 3] is driving efforts to repurpose FDA approved drugs — to find new uses for which they weren ’ t intended, and to thereby reduce the overall cost of commercialization, and shorten the lag between drug discovery and…”
BackgroundCombining Molecular Scaffolds from FDA Approved Drugs: Application to Drug Discovery
Taylor, R. D., MacCoss, M., & Lawson, A. D. G. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01367 · Cited by 62
Wong, A. L., Xiang, X., Ong, P. S., Mitchell, E. Q. Y., Syn, N. L. X., Wee, I. J. Y., Kumar, A. P., Yong, W. P., Sethi, G., Goh, B. C., et al. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040221 · Cited by 60
“According to a review article, two major underlying reasons accounting for drug attrition were identified [3].”
BackgroundNatural Products as Modulators of Sirtuins
Karaman, B., Sippl, W., & Ntie‐Kang, F. (2020) · Molecules · doi:10.3390/molecules25143287 · Cited by 66
“Higher attrition rates in the late stages of the drug discovery pipeline especially in Phase II and Phase III clinical trials have also placed substantial stress on pharmaceutical and biotech companies [1-3].”
BackgroundR&D efficiency of leading pharmaceutical companies – A 20-year analysis
Schuhmacher, A., Wilisch, L., Kuss, M., Kandelbauer, A., Hinder, M., & Gassmann, O. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.05.005 · Cited by 71
Donato, M. T., & Gómez-Lechón, M. J. (2012) · Current Drug Metabolism · doi:10.2174/138920012802850001 · Cited by 64
The use of machine learning and nonlinear statistical tools for ADME prediction
Sakiyama, Y. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902753261 · Cited by 58
“Failure to find promising candidates in the drug discovery process will cause substantial damage in the current business environment [1].”
BackgroundBioreactor engineering of stem cell environments
Tandon, N. M., Marolt, D., Cimetta, E., & Vunjak‐Novakovic, G. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.03.007 · Cited by 66
“Part of the problem is that, in the conventional target-centric drug discovery model, compounds are typically not tested in a patient population until Phase II clinical trials have been carried out, thus contributing to a high drug attrition rate (Kola, 2008; Kola and Landis, 2004).”
BackgroundLi, H., Sun, J., Fan, X., Sui, X., Zhang, L., Wang, Y., & He, Z. (2008) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-008-9225-4 · Cited by 63
Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib
Carlisle, B. G., Demko, N., Freeman, G., Hakala, A., MacKinnon, N., Ramsay, T., Hey, S. P., London, A. J., & Kimmelman, J. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv292 · Cited by 68
“In another, only one in 10 drugs entering clinical development is ultimately licensed for clinical application; the fraction of drugs receiving licensure in areas where clinical need is especially pressing—cancer and neurological drugs—is lower still (5,6).”
BackgroundSerendipity in Cancer Drug Discovery: Rational or Coincidence?
Prasad, S., Gupta, S. C., & Aggarwal, B. B. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.03.004 · Cited by 65
Gerlai, R. T. (2017) · Behavioural Processes · doi:10.1016/j.beproc.2017.01.016 · Cited by 64
Computer-Aided Drug Design: An Overview
Talevi, A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7756-7_1 · Cited by 70
Drug Repurposing in Parkinson’s Disease
Athauda, D. S., & Foltynie, T. (2018) · CNS Drugs · doi:10.1007/s40263-018-0548-y · Cited by 62
Drug rechanneling: A novel paradigm for cancer treatment
Kaushik, I., Ramachandran, S., Prasad, S., & Srivastava, S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.011 · Cited by 65
Bailey, J., Thew, M., & Balls, M. (2015) · Alternatives to Laboratory Animals · doi:10.1177/026119291504300607 · Cited by 58
Validating ADME QSAR Models Using Marketed Drugs
Siramshetty, V. B., Williams, J., Nguyễn, Ð.-T., Neyra, J., Southall, N. T., Mathé, E. A., Xu, X., & Shah, P. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211017520 · Cited by 67
Computer-Aided Drug Discovery and Design: Recent Advances and Future Prospects
Talevi, A. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3441-7_1 · Cited by 70
Kornegay, J. N., Spurney, C. F., Nghiem, P. P., Brinkmeyer‐Langford, C., Hoffman, E. P., & Nagaraju, K. (2014) · ILAR Journal · doi:10.1093/ilar/ilu011 · Cited by 67
“With more careful analysis of the PK properties of drugs and development of tools to better predict drug absorption and clearance, drug–drug interactions, and scaling of PK parameters from animals to man (Walker 2004), PK issues accounted for only 10% of drug failures in 2000 (Kola and Landis 2004).”
BackgroundA Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases
Berenstein, A. J., Magariños, M. P., Chernomoretz, A., & Agüero, F. (2016) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0004300 · Cited by 67
“Furthermore, there has been limited commercial interest in developing improved therapeutics, mostly because of the costly and risky nature of the drug discovery process [5,6] and the expected low return of investment when dealing with poor patient populations [7].”
BackgroundDrug Metabolism and Pharmacokinetics Quick Guide
Khojasteh, S. C., Wong, H. H., & Hop, C. E. C. A. (2011) · Springer eBooks · doi:10.1007/978-1-4419-5629-3 · Cited by 76
Pang, W., Lv, J., Du, S., Wang, J., Wang, J., & Zeng, Y. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00217 · Cited by 58
Metadata
- Authors
- Kola, I., & Landis, J.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Kola, Ismail
- ORCID
- Landis, John
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-08
- Volume
- 3
- Issue
- 8
- Pages
- 711-716
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1895993106
- Cited by
- 4,167
- References
- 7
- Citations by year
- 2026: 121 · 2025: 129 · 2024: 126 · 2023: 159 · 2022: 165 · 2021: 188 · 2020: 179 · 2019: 203 · 2018: 183 · 2017: 194 · 2016: 256 · 2015: 294 · 2014: 279 · 2013: 307 · 2012: 300
- FWCI
- 199.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Keywords
- pharmaceutical industry, attrition rates, R&D productivity, drug development costs, health care cost containment, drug costs, R&D investment
- MeSH terms
- Clinical Trials as Topic, Drug Industry, Humans, Pharmacokinetics, Drug Design, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.